Table 1.
Effects of K+ channel blockers on SCC following activation by forskolin in nasal epithelia
| Genotype | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Blocker | Concentration | Null | ΔF | Basal SCC (μA cm-2) | Amiloride ΔSCC (μA cm-2) | Forskolin (plateau) ΔSCC (μA cm-2) | 1st blocker ΔSCC (μA cm-2) | Ba2+ΔSCC (μA cm-2) | |
| Charybdotoxin | 50 nM | WT | 3 | 3 | 3.8 ± 3.6 | −3.5 ± 1.8 | 31.4 ± 10.5 | 0 ± 0 | −21.8 ± 6.4 |
| Charybdotoxin | 50 nM | CF | — | 3 | 14.9 ± 19.2 | −21.8 ± 15.1 | 64.8 ± 29.6 | 0 ± 0 | −38.7 ± 17.4 |
| 293B | 100 μM | WT | 1 | 4 | 14.3 ± 6.2 | −6.1 ± 2.6 | 51.7 ± 13.0 | 0 ± 0 | −33.1 ± 6.2 |
| 293B | 100 μM | CF | — | 2 | 43.1 | −23.3 | 70.3 | 0 | n.d. |
| Azimilide | 100 μM | WT | 4 | 2 | 5.5 ± 7.6 | −3.5 ± 1.9 | 52.8 ± 15.7 | −7.8 ± 2.7 | −25.8 ± 6.2 |
The genetic background of the wild-type (WT) and CF animals is indicated. 1st blocker refers to the agent given at the left-hand side of the table. Ba2+ was added after the effect of the first blocker had reached equilibrium. n.d., not determined.